Clinical Trials
6 trialsNCT05338931 2022-05-26
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
AbClon
Phase 1/2 Recruiting
NCT01003769 2020-06-16
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 1/2 Terminated
NCT00561197 2013-01-04
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
Ascenta Therapeutics
Phase 1/2 Terminated
NCT00286793 2011-06-29
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Ascenta Therapeutics
Phase 1/2 Completed
NCT00286806 2010-08-24
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Ascenta Therapeutics
Phase 1/2 Completed
NCT00397293 2010-08-24
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Ascenta Therapeutics
Phase 1/2 Completed